Work

Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.2055

Authors: Samuel Aaron Goldlust, Louis B. Nabors, Nimish Mohile, Tara L. Benkers, Sigmund H. Hsu, Sandra Silberman, Samuel Singer, George Farmer

Institutions: Hackensack University Medical Center, University of Alabama at Birmingham, University of Rochester, Swedish Medical Center, Cortice Biosciences, Inc. (United States)

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2507200596

Cites:

Cited by: 6

Related to: 20